Xinmingyuan Pharmaceutical

Beijing Xinmingyuan Pharmaceutical Technology is a clinical-stage biopharmaceutical company headquartered in Beijing, China, dedicated to the development of innovative small molecule drugs. The company focuses on high-selectivity kinase inhibitors to address significant unmet needs in autoimmune diseases, inflammatory conditions, and oncology. Its lead program, XMY001, is a potent and selective TYK2 inhibitor currently in Phase 2 clinical trials for psoriasis and other immune-mediated disorders. Xinmingyuan's R&D strategy integrates structure-based drug design with deep expertise in the JAK/STAT signaling pathway to create a robust pipeline of next-generation therapeutics. The company was founded by industry veterans with extensive experience in global drug discovery and development. Xinmingyuan aims to deliver best-in-class treatments by optimizing the safety and efficacy profiles of its candidates through superior molecular selectivity.